Abstract
Objective To analyze the clinical and laboratory features of Lupus mesenteric vasculitis (LMV) with urinary tract involvement. Methods Eighty two LMV patients hospitalized to our hospital from 2009 to 2015 were recruited into this study. The clinical and laboratory features of LMV with or without urinary tract involvement were retrospectively analyzed. Results The prevalence of LMV in systemic lupus erythematosus (SLE) patients with SLE (LMVU group) was 4.67% (82/1 755). The prevalence of LMV with urinary tract involvement was 29.3% (24/81) and intestinal pseudo-obstruction (IPO) with urinary tract involvement (IPOU group) was 13.4% (11/24). There was no difference in age, gender and disease duration between the LMV, LMVU and IPOU group. Twenty-four hours urinary protein content in the LMVU and IPOU group was (1.3±2.2) g/d and (1.6±2.8) g/d, respectively, which was higher than those in the LMV without urinary tract involvement group [(0.8±1.2) g/d] (t=2.871, P=0.04 and t=2.011, P=0.02, respectively). Percentage of severe active lupus defined as systemic lupus erythematosus disease activity index (SLEDAI)>15 showed a significant increased trend in these three groups (29.6%, 41.7% and 63.6%, respectively) and percentage of anti-SSA was also increased in the IPOU group compared with those in the LMV group (90.9% vs 64.2%, χ2=4.115, P=0.02). Multivariate logistic regression analysis indicated that SLEDAI>15 and 24h urinary protein content were risk factors for LMV with urinary tract involvement (OR=1.12, P=0.03 and OR=1.21, P=0.05, respectively). Conclusion Urinary tract involvement is often accompanied with LMV and associates with severe disease activity. Key words: Lupus erythematosus, systemic; Lupus mesenteric vasculitis; Urinary tract involvement
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call